nifedipine has been researched along with Preterm Birth in 53 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the cost-effectiveness of treatment with nifedipine compared with atosiban in women with threatened preterm birth." | 9.30 | Cost effectiveness of nifedipine compared with atosiban in the treatment of threatened preterm birth (APOSTEL III trial). ( Bloemenkamp, K; de Boer, MA; Franx, A; Gyselaers, W; Kok, M; Mol, B; Nijman, T; Oudijk, MA; Porath, MM; Sueters, M; van Baaren, GJ; van Vliet, E; Woiski, M, 2019) |
| " Women with threatened preterm birth (gestational age 25-34 weeks) were randomly assigned (1:1) to either oral nifedipine or intravenous atosiban for 48 h." | 9.22 | Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. ( Bax, CJ; Beek, EV; Bloemenkamp, KWM; Duvekot, JJ; Franssen, MTM; Franx, A; Gyselaers, W; Heida, KY; Jacquemyn, Y; Kok, JH; Kok, M; Mol, BW; Nijman, TAJ; Opmeer, BC; Oudijk, MA; Papatsonis, DN; Porath, MM; Scheepers, HCJ; Schuit, E; van der Post, JAM; van Vliet, EOG; Woiski, M, 2016) |
| " Nifedipine did not increase the odds of developing pulmonary edema [adjusted odds ratio (OR)=1." | 7.80 | Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births. ( Abenhaim, HA; Gangal, M; Xiao, C, 2014) |
| "Preterm birth is the most common cause of neonatal morbidity and mortality." | 7.01 | The effectiveness of nifedipine/indomethacin combination therapy and nifedipine monotherapy for postponing preterm birth (25-34 weeks of gestation) in Sudanese women: a randomized clinical trial study protocol. ( Abdelrahiem, SK; Adam, I; Elfaki, T; Elhassan, EM; Ibrahim, MH, 2021) |
| "Nifedipine is a calcium channel blocking agent used to delay threatened spontaneous preterm birth, however, has limited efficacy and lacks preclinical data regarding mechanisms of action." | 5.91 | Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth. ( Arman, BM; Beard, S; Binder, NK; de Alwis, N; Debruin, DA; Hannan, NJ; Hayes, A; Kaitu'u-Lino, TJ; Tong, S, 2023) |
| " Neither nifedipine nor atosiban can be considered as the preferred treatment for women with threatened preterm birth." | 5.34 | Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial. ( Kleinrouweler, CE; Klumper, J; Mol, BW; Naaktgeboren, CA; Nijman, TA; Oudijk, MA; Pajkrt, E; Roos, C; Roseboom, TJ; Tichelaar, MA; van Baar, AL; van Wassenaer-Leemhuis, AG; van Winden, T; Van't Hooft, J, 2020) |
| "To assess the cost-effectiveness of treatment with nifedipine compared with atosiban in women with threatened preterm birth." | 5.30 | Cost effectiveness of nifedipine compared with atosiban in the treatment of threatened preterm birth (APOSTEL III trial). ( Bloemenkamp, K; de Boer, MA; Franx, A; Gyselaers, W; Kok, M; Mol, B; Nijman, T; Oudijk, MA; Porath, MM; Sueters, M; van Baaren, GJ; van Vliet, E; Woiski, M, 2019) |
| " The aim of this study was to evaluate whether tocolysis with nifedipine or atosiban in women with threatened preterm birth can reduce the incidence of overall brain injury in neonates born prematurely." | 5.27 | Effect of nifedipine and atosiban on perinatal brain injury: secondary analysis of the APOSTEL-III trial. ( Benders, MJN; de Haan, TR; Franx, A; Goedhart, MM; Mol, BW; Naaktgeboren, CN; Nijman, TAJ; Oudijk, MA; Vijlbrief, DC, 2018) |
| "Nifedipine may be better for delayed delivery and less likely to produce adverse pregnancy outcomes, followed by indomethacin." | 5.22 | Four kinds of tocolytic therapy for preterm delivery: Systematic review and network meta-analysis. ( Pei, S; Xiong, Z; Zhu, Z, 2022) |
| "In this IPDMA, we found no differences in composite outcome between nifedipine and atosiban in the treatment of threatened preterm birth." | 5.22 | Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis. ( Al-Omari, WR; Kashanian, M; Kleinrouweler, CE; Mol, BW; Nijman, TAJ; Oudijk, MA; Pajkrt, E; Roos, C; Salim, R; van Winden, TMS, 2022) |
| " Women with threatened preterm birth (gestational age 25-34 weeks) were randomly assigned (1:1) to either oral nifedipine or intravenous atosiban for 48 h." | 5.22 | Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. ( Bax, CJ; Beek, EV; Bloemenkamp, KWM; Duvekot, JJ; Franssen, MTM; Franx, A; Gyselaers, W; Heida, KY; Jacquemyn, Y; Kok, JH; Kok, M; Mol, BW; Nijman, TAJ; Opmeer, BC; Oudijk, MA; Papatsonis, DN; Porath, MM; Scheepers, HCJ; Schuit, E; van der Post, JAM; van Vliet, EOG; Woiski, M, 2016) |
| " The aim of this trial was to study the effect of prolonged tocolysis with nifedipine versus placebo in women with PPROM on perinatal outcome and prolongation of pregnancy." | 5.22 | Nifedipine versus placebo in the treatment of preterm prelabor rupture of membranes: a randomized controlled trial: Assessment of perinatal outcome by use of tocolysis in early labor-APOSTEL IV trial. ( Bax, CJ; Bloemenkamp, KW; de Lange, TS; Franx, A; Kok, M; Mol, BW; Naaktgeboren, CA; Nijman, TA; Oude Rengerink, K; Oudijk, MA; Scheepers, HC; van Eyck, J; van Vliet, EO; Woiski, M, 2016) |
| "Our study results suggested that the use of nifedipine as a single tocolytic regimen is as effective as the combination regimen in the delay of preterm births and has much less side effects." | 5.20 | Single versus combination tocolytic regimen in the prevention of preterm births in women: a prospective cohort study. ( Abdul Rahman, MF; Chee, JJ; Lim, ML; Ng, QJ; Tan, KH, 2015) |
| "Women with a singleton pregnancy in threatened preterm labour (24(+0) to 33(+6) weeks) with a positive fetal fibronectin test were randomised to nifedipine or placebo." | 5.19 | The NIFTY study: a multicentre randomised double-blind placebo-controlled trial of nifedipine maintenance tocolysis in fetal fibronectin-positive women in threatened preterm labour. ( Hayward, L; McCowan, L; Mol, BW; Parry, E; Roos, C; Stone, P, 2014) |
| "To estimate whether maintenance nifedipine tocolysis after arrested preterm labor prolongs pregnancy and improves neonatal outcomes." | 5.13 | Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial. ( Caughey, AB; Chitkara, U; Druzin, ML; El-Sayed, YY; Lyell, DJ; Mannan, J; Pullen, KM, 2008) |
| " The incidence of severe hypertension was significantly lower when nifedipine and methyldopa were administered, although preeclampsia risk was similar among antihypertensive agents." | 5.05 | Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. ( Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020) |
| "To evaluate the effectiveness of maintenance tocolytic therapy with oral nifedipine on the reduction of adverse neonatal outcomes and the prolongation of pregnancy by performing an individual patient data meta-analysis (IPDMA)." | 4.93 | Nifedipine maintenance tocolysis and perinatal outcome: an individual participant data meta-analysis. ( Carr, DB; Clark, AL; Dijkema, GH; El-Sayed, YY; Heida, KY; Lyell, DJ; Mahdy, ZA; McCowan, L; Mol, BW; Oudijk, MA; Parry, EC; Roos, C; Sayin, NC; Schuit, E; Uma, M; van der Post, J; van Vliet, E; Varol, GF, 2016) |
| " No difference in the incidence of preterm birth was found when calcium channel blocker (nifedipine) maintenance therapy was compared with no treatment." | 4.82 | Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour. ( Crowther, CA; Gaunekar, NN, 2004) |
| " We evaluated the ability of oxytocin receptor-targeted liposomes to localize to uterine tissue in vivo, and assessed if targeted liposomes loaded with indomethacin were capable of preventing lipopolysaccharide-induced preterm birth in mice." | 3.85 | Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor. ( Butler, T; Hua, S; Ilicic, M; Paul, JW; Robertson, S; Smith, R; Tolosa, JM, 2017) |
| " Nifedipine did not increase the odds of developing pulmonary edema [adjusted odds ratio (OR)=1." | 3.80 | Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births. ( Abenhaim, HA; Gangal, M; Xiao, C, 2014) |
| "To analyse the expression of 15 genes encoding receptors and enzymes associated with the molecular mechanism of the tocolytic drugs atosiban (oxytocin receptor antagonist), nifedipine (calcium channel blocker) and celecoxib (selective cyclo-oxygenase-2 inhibitor) in preterm labor patients with premature rupture of fetal membranes in relation to symptoms of intrauterine infection and preterm labor risk factors." | 3.78 | Expression of selected genes in preterm premature rupture of fetal membranes. ( Chyczewski, L; Kowalczuk, O; Kuć, P; Laudański, P; Laudański, T, 2012) |
| "Preterm birth was induced in Sprague-Dawley rats with a combination of mifepristone and prostaglandin-E(2)." | 3.76 | Potentiation of the uterus-relaxing effects of β-adrenergic agonists with nifedipine: studies on rats and the human myometrium. ( Falkay, G; Gáspár, R; Hajagos-Tóth, J; Kormányos, Z; Pál, A, 2010) |
| "Preterm birth is the most common cause of neonatal morbidity and mortality." | 3.01 | The effectiveness of nifedipine/indomethacin combination therapy and nifedipine monotherapy for postponing preterm birth (25-34 weeks of gestation) in Sudanese women: a randomized clinical trial study protocol. ( Abdelrahiem, SK; Adam, I; Elfaki, T; Elhassan, EM; Ibrahim, MH, 2021) |
| "To study the tocolytic action of nifedipine combined with sildenafil citrate (SC) and if the combination is superior to nifedipine alone in inhibiting threatened preterm labour (PTL)." | 2.90 | Nifedipine alone or combined with sildenafil citrate for management of threatened preterm labour: a randomised trial. ( El-Khadry, SW; Maher, MA; Sayyed, TM, 2019) |
| "Management of preterm labor and prevention from preterm delivery in order to lower these risks have always been under serious concern." | 2.79 | Comparison between nitroglycerin dermal patch and nifedipine for treatment of preterm labor: a randomized clinical trial. ( Kashanian, M; Sheikhansari, N; Zamen, Z, 2014) |
| "To compare the effectiveness and adverse effects of nifedipine versus indomethacin in the treatment of preterm labor." | 2.76 | Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. ( Bahasadri, S; Kashanian, M; Zolali, B, 2011) |
| " β2-agonists are relatively safe for the fetus but have rare and potentially serious maternal adverse effects." | 2.53 | The safety of tocolytics used for the inhibition of preterm labour. ( Jørgensen, JS; Lamont, CD; Lamont, RF, 2016) |
| "When preterm labor is actually threatening, current pharmacological therapies focus on inhibition of preterm contractions." | 2.50 | Preterm labor: current pharmacotherapy options for tocolysis. ( Boormans, EM; de Lange, TS; Mol, BW; Oudijk, MA; van Vliet, EO, 2014) |
| " Another important focus for future trials is identifying optimal dosage regimens of different types of CCBs (high versus low, particularly addressing speed of onset of uterine quiescence) and formulation (capsules versus tablets)." | 2.50 | Calcium channel blockers for inhibiting preterm labour and birth. ( Carbonne, B; Flenady, V; Jardine, LA; Murray, L; Papatsonis, DN; Stock, OM; Wojcieszek, AM, 2014) |
| "Preterm birth is the major cause of perinatal mortality and morbidity in the developed world." | 2.44 | Developments in the pharmacotherapeutic management of spontaneous preterm labor. ( Kam, KY; Lamont, RF, 2008) |
| "Nifedipine was introduced as a tocolytic agent at a time when beta-agonists and magnesium sulphate dominated the arena for the prevention of preterm birth." | 2.43 | Nifedipine trials: effectiveness and safety aspects. ( Bolte, AC; Lenglet, JE; van Geijn, HP, 2005) |
| "Nifedipine is a calcium channel blocking agent used to delay threatened spontaneous preterm birth, however, has limited efficacy and lacks preclinical data regarding mechanisms of action." | 1.91 | Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth. ( Arman, BM; Beard, S; Binder, NK; de Alwis, N; Debruin, DA; Hannan, NJ; Hayes, A; Kaitu'u-Lino, TJ; Tong, S, 2023) |
| "Thirty-seven pregnant women in preterm labor participated in a prospective longitudinal study." | 1.34 | [Treatment of preterm delivery with calcium channel blockers--Nifedipine]. ( Diavolov, V; Dimitrov, A; Ivanov, S; Markov, D; Nikolov, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (13.21) | 29.6817 |
| 2010's | 32 (60.38) | 24.3611 |
| 2020's | 14 (26.42) | 2.80 |
| Authors | Studies |
|---|---|
| Xiong, Z | 1 |
| Pei, S | 1 |
| Zhu, Z | 1 |
| Dublin, S | 1 |
| Idu, A | 1 |
| Avalos, LA | 1 |
| Cheetham, TC | 1 |
| Easterling, TR | 1 |
| Chen, L | 1 |
| Holt, VL | 1 |
| Nance, N | 1 |
| Bider-Canfield, Z | 1 |
| Neugebauer, RS | 1 |
| Reynolds, K | 1 |
| Badon, SE | 1 |
| Shortreed, SM | 1 |
| Hossain, MR | 1 |
| Tolosa, JM | 2 |
| Young, RC | 1 |
| Smith, R | 2 |
| Paul, JW | 2 |
| van Winden, TMS | 1 |
| Nijman, TAJ | 3 |
| Kleinrouweler, CE | 2 |
| Salim, R | 1 |
| Kashanian, M | 4 |
| Al-Omari, WR | 1 |
| Pajkrt, E | 2 |
| Mol, BW | 10 |
| Oudijk, MA | 8 |
| Roos, C | 4 |
| Taguchi, R | 1 |
| Shigemi, D | 1 |
| Yasunaga, H | 1 |
| Arman, BM | 1 |
| Binder, NK | 1 |
| de Alwis, N | 1 |
| Beard, S | 1 |
| Debruin, DA | 1 |
| Hayes, A | 1 |
| Tong, S | 1 |
| Kaitu'u-Lino, TJ | 1 |
| Hannan, NJ | 1 |
| Siricilla, S | 1 |
| Hansen, CJ | 1 |
| Rogers, JH | 1 |
| De, D | 1 |
| Simpson, CL | 1 |
| Waterson, AG | 1 |
| Sulikowski, GA | 1 |
| Crockett, SL | 1 |
| Boatwright, N | 1 |
| Reese, J | 1 |
| Paria, BC | 1 |
| Newton, J | 1 |
| Herington, JL | 1 |
| Santos, S | 1 |
| Haslinger, C | 1 |
| Mennet, M | 1 |
| von Mandach, U | 1 |
| Hamburger, M | 1 |
| Simões-Wüst, AP | 1 |
| Leal-Júnior, CC | 1 |
| Amorim, MMR | 1 |
| Souza, GFA | 1 |
| Lima, AKS | 1 |
| Souza, ASR | 1 |
| van Winden, T | 1 |
| Klumper, J | 1 |
| Tichelaar, MA | 1 |
| Naaktgeboren, CA | 2 |
| Nijman, TA | 2 |
| van Baar, AL | 1 |
| van Wassenaer-Leemhuis, AG | 1 |
| Roseboom, TJ | 1 |
| Van't Hooft, J | 1 |
| Bellos, I | 1 |
| Pergialiotis, V | 1 |
| Papapanagiotou, A | 1 |
| Loutradis, D | 1 |
| Daskalakis, G | 1 |
| Emeruwa, UN | 1 |
| Krenitsky, NM | 1 |
| Sheen, JJ | 1 |
| Grin, L | 1 |
| Laish-Farkash, A | 1 |
| Bruoha, S | 1 |
| Rabinovich, M | 1 |
| Harlev, A | 1 |
| Anteby, E | 1 |
| Yosefy, C | 1 |
| Shenhav, S | 1 |
| Ibrahim, MH | 1 |
| Elfaki, T | 1 |
| Elhassan, EM | 1 |
| Abdelrahiem, SK | 1 |
| Adam, I | 1 |
| Goedhart, MM | 1 |
| Naaktgeboren, CN | 1 |
| de Haan, TR | 1 |
| Vijlbrief, DC | 1 |
| Benders, MJN | 1 |
| Franx, A | 4 |
| Dehaene, I | 1 |
| Bergman, L | 1 |
| Turtiainen, P | 1 |
| Ridout, A | 1 |
| Lorthe, E | 1 |
| Govindaswami, B | 1 |
| Jegatheesan, P | 1 |
| Nudelman, M | 1 |
| Narasimhan, SR | 1 |
| Maher, MA | 1 |
| Sayyed, TM | 1 |
| El-Khadry, SW | 1 |
| Nijman, T | 1 |
| van Baaren, GJ | 1 |
| van Vliet, E | 2 |
| Kok, M | 3 |
| Gyselaers, W | 2 |
| Porath, MM | 3 |
| Woiski, M | 3 |
| de Boer, MA | 1 |
| Bloemenkamp, K | 1 |
| Sueters, M | 1 |
| Mol, B | 1 |
| Shirvani, S | 1 |
| Sheikhansari, N | 2 |
| Javanmanesh, F | 1 |
| Haas, DM | 1 |
| Naik Gaunekar, N | 1 |
| Raman, P | 1 |
| Bain, E | 1 |
| Crowther, CA | 2 |
| Jørgensen, JS | 2 |
| Weile, LK | 1 |
| Lamont, RF | 3 |
| Parry, E | 1 |
| Stone, P | 1 |
| Hayward, L | 1 |
| McCowan, L | 2 |
| van Vliet, EO | 2 |
| Boormans, EM | 1 |
| de Lange, TS | 2 |
| Xiao, C | 1 |
| Gangal, M | 1 |
| Abenhaim, HA | 1 |
| Danti, L | 1 |
| Zonca, M | 1 |
| Barbetti, L | 1 |
| Lojacono, A | 1 |
| Marini, S | 1 |
| Cappello, N | 1 |
| Bianchi, U | 1 |
| Benedetto, C | 1 |
| Zamen, Z | 1 |
| Wilms, FF | 1 |
| Vis, JY | 1 |
| de Wit-Zuurendonk, L | 1 |
| Flenady, V | 1 |
| Wojcieszek, AM | 1 |
| Papatsonis, DN | 2 |
| Stock, OM | 1 |
| Murray, L | 1 |
| Jardine, LA | 1 |
| Carbonne, B | 2 |
| Ng, QJ | 1 |
| Abdul Rahman, MF | 1 |
| Lim, ML | 1 |
| Chee, JJ | 1 |
| Tan, KH | 1 |
| Walker, KF | 1 |
| Thornton, JG | 1 |
| van Vliet, EOG | 1 |
| Schuit, E | 2 |
| Heida, KY | 2 |
| Opmeer, BC | 1 |
| Bax, CJ | 2 |
| Bloemenkamp, KWM | 1 |
| Scheepers, HCJ | 1 |
| Jacquemyn, Y | 1 |
| Beek, EV | 1 |
| Duvekot, JJ | 1 |
| Franssen, MTM | 1 |
| Kok, JH | 1 |
| van der Post, JAM | 1 |
| Lamont, CD | 1 |
| Vink, JY | 1 |
| Qin, S | 1 |
| Brock, CO | 1 |
| Zork, NM | 1 |
| Feltovich, HM | 1 |
| Chen, X | 1 |
| Urie, P | 1 |
| Myers, KM | 1 |
| Hall, TJ | 1 |
| Wapner, R | 1 |
| Kitajewski, JK | 1 |
| Shawber, CJ | 1 |
| Gallos, G | 1 |
| Karahanoglu, E | 1 |
| Altinboga, O | 1 |
| Akpinar, F | 1 |
| Demirdag, E | 1 |
| Ozdemirci, S | 1 |
| Akyol, A | 1 |
| Yalvac, S | 1 |
| Dijkema, GH | 1 |
| van der Post, J | 1 |
| Parry, EC | 1 |
| Lyell, DJ | 3 |
| El-Sayed, YY | 2 |
| Carr, DB | 1 |
| Clark, AL | 1 |
| Mahdy, ZA | 1 |
| Uma, M | 1 |
| Sayin, NC | 1 |
| Varol, GF | 1 |
| Oude Rengerink, K | 1 |
| Bloemenkamp, KW | 1 |
| van Eyck, J | 1 |
| Scheepers, HC | 1 |
| Hua, S | 1 |
| Ilicic, M | 1 |
| Butler, T | 1 |
| Robertson, S | 1 |
| Nikolov, A | 1 |
| Markov, D | 1 |
| Dimitrov, A | 1 |
| Ivanov, S | 1 |
| Diavolov, V | 1 |
| Pullen, KM | 1 |
| Mannan, J | 1 |
| Chitkara, U | 1 |
| Druzin, ML | 1 |
| Caughey, AB | 1 |
| de Heus, R | 1 |
| Mulder, EJ | 1 |
| Derks, JB | 1 |
| Visser, GH | 1 |
| Blumenfeld, YJ | 1 |
| Le Ray, C | 1 |
| Maillard, F | 1 |
| Verspyck, E | 1 |
| Cabrol, D | 1 |
| Goffinet, F | 1 |
| Nassar, AH | 2 |
| Aoun, J | 1 |
| Usta, IM | 2 |
| Hajagos-Tóth, J | 1 |
| Kormányos, Z | 1 |
| Falkay, G | 1 |
| Pál, A | 1 |
| Gáspár, R | 1 |
| Khalil, A | 1 |
| Manuck, TA | 1 |
| Henry, E | 1 |
| Gibson, J | 1 |
| Varner, MW | 1 |
| Porter, TF | 1 |
| Jackson, GM | 1 |
| Esplin, MS | 1 |
| Bahasadri, S | 1 |
| Zolali, B | 1 |
| Kuć, P | 1 |
| Laudański, P | 1 |
| Kowalczuk, O | 1 |
| Chyczewski, L | 1 |
| Laudański, T | 1 |
| Gaunekar, NN | 1 |
| van Geijn, HP | 1 |
| Lenglet, JE | 1 |
| Bolte, AC | 1 |
| Kam, KY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bryophyllum Pinnatum Treatment of Anxiety Related to Signs of Preterm Birth: a Randomised, Double-blind, Placebo-controlled Study as Investigator-Initiated Trial[NCT05110599] | Phase 2 | 60 participants (Actual) | Interventional | 2022-07-12 | Terminated (stopped due to Slow recruitment and expired study medication.) | ||
| Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation: a Double-blinded Randomized Controlled Trial[NCT03976063] | Phase 3 | 850 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| Vaginal Indomethacin Versus Oral Nifedipine for Preterm Labor; a Randomized Controlled Trial[NCT04404686] | Phase 2/Phase 3 | 300 participants (Anticipated) | Interventional | 2020-10-31 | Not yet recruiting | ||
| The Tocolytic Efficacy of Nifedipine in the Management of Threatened and Advanced Preterm Labor: A Study on 444 Singleton Pregnant Women With Intact Membranes[NCT04644354] | 444 participants (Anticipated) | Observational | 2020-12-15 | Not yet recruiting | |||
| Nifedipine for the Maintenance Tocolysis of Preterm Labor: Comparison to Placebo in a Prospective, Randomized Double Blind Trial[NCT00185952] | 70 participants (Actual) | Interventional | 2001-11-30 | Completed | |||
| Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor[NCT01840228] | 38 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Low enrollment rate) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A composite neonatal outcome comprising neonatal death, respiratory distress syndrome, bronchopulmonary dysplasia, severe (grade III/IV) interventricular hemorrhage, necrotizing enterocolitis, and sepsis. (NCT01840228)
Timeframe: Followed for duration of neonatal hospital stay, estimated maximum 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Micronized Progesterone Suppository - SINGLETON | 5 |
| Placebo Suppository - SINGLETON | 5 |
| Micronized Progesterone Suppository - TWINS | 3 |
| Placebo Suppository - TWINS | 7 |
(NCT01840228)
Timeframe: 2 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Micronized Progesterone Suppository | 6 |
| Placebo Suppository | 4 |
(NCT01840228)
Timeframe: Day of delivery in current pregnancy
| Intervention | grams (Mean) |
|---|---|
| Micronized Progesterone Suppository - SINGLETON | 2454.9 |
| Placebo Suppository - SINGLETON | 2523.1 |
| Micronized Progesterone Suppository - TWINS | 2164.4 |
| Placebo Suppository - TWINS | 1974.1 |
(NCT01840228)
Timeframe: Followed for duration of neonatal hospital stay, estimated maximum 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Micronized Progesterone Suppository - SINGLETON | 2 |
| Placebo Suppository - SINGLETON | 2 |
| Micronized Progesterone Suppository - TWINS | 0 |
| Placebo Suppository - TWINS | 1 |
Evaluated in women enrolled prior to 32 weeks gestation (NCT01840228)
Timeframe: Duration of current pregnancy, anticipated maximum 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Micronized Progesterone Suppository | 3 |
| Placebo Suppository | 6 |
(NCT01840228)
Timeframe: Duration of current pregnancy, anticipated maximum 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Micronized Progesterone Suppository | 11 |
| Placebo Suppository | 10 |
(NCT01840228)
Timeframe: Duration of current pregnancy, anticipated maximum 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Micronized Progesterone Suppository | 0 |
| Placebo Suppository | 0 |
(NCT01840228)
Timeframe: Duration of current pregnancy, anticipated maximum 18 weeks
| Intervention | weeks (Median) |
|---|---|
| Micronized Progesterone Suppository | 5.3 |
| Placebo Suppository | 5.0 |
17 reviews available for nifedipine and Preterm Birth
| Article | Year |
|---|---|
Four kinds of tocolytic therapy for preterm delivery: Systematic review and network meta-analysis.
Topics: Female; Humans; Indomethacin; Infant; Infant, Newborn; Network Meta-Analysis; Nifedipine; Obstetric | 2022 |
Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis.
Topics: Female; Humans; Infant, Newborn; Nifedipine; Perinatal Death; Pregnancy; Premature Birth; Systematic | 2022 |
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease | 2020 |
Advances in Management for Preterm Fetuses at Risk of Delivery.
Topics: Anti-Bacterial Agents; Anticonvulsants; Betamethasone; Dexamethasone; Female; Fetal Membranes, Prema | 2020 |
Maintaining and repeating tocolysis: A reflection on evidence.
Topics: Drug Administration Schedule; Evidence-Based Practice; Female; Humans; Nifedipine; Obstetric Labor, | 2017 |
Prevention of Prematurity: Advances and Opportunities.
Topics: Anti-Infective Agents; Aspirin; Cerclage, Cervical; Cesarean Section; Female; Humans; Indomethacin; | 2018 |
Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour.
Topics: Calcium Channel Blockers; Female; Humans; Incidence; Infant Mortality; Infant, Newborn; Labor, Obste | 2013 |
Preterm labor: current pharmacotherapy options for tocolysis.
Topics: Female; Humans; Infant, Newborn; Nifedipine; Obstetric Labor, Premature; Pregnancy; Premature Birth; | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
Calcium channel blockers for inhibiting preterm labour and birth.
Topics: Adrenergic beta-Agonists; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Pre | 2014 |
The safety of tocolytics used for the inhibition of preterm labour.
Topics: Animals; Female; Humans; Infant, Newborn; Nifedipine; Obstetric Labor, Premature; Pregnancy; Prematu | 2016 |
Nifedipine maintenance tocolysis and perinatal outcome: an individual participant data meta-analysis.
Topics: Adult; Female; Gestational Age; Humans; Infant, Newborn; Infant, Newborn, Diseases; Nifedipine; Peri | 2016 |
Prematurity prevention: the role of acute tocolysis.
Topics: Acute Disease; Administration, Oral; Calcium Channel Blockers; Clinical Trials as Topic; Female; Hum | 2009 |
Calcium channel blockers for the management of preterm birth: a review.
Topics: Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Premature; Practice Patterns, | 2011 |
Oxytocin antagonists for the management of preterm birth: a review.
Topics: Female; Hormone Antagonists; Humans; Indoles; Nifedipine; Oligopeptides; Oxytocin; Premature Birth; | 2011 |
Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour.
Topics: Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric Labor, Premature; Pregnancy; Prematu | 2004 |
Nifedipine trials: effectiveness and safety aspects.
Topics: Humans; Meta-Analysis as Topic; Nifedipine; Premature Birth; Randomized Controlled Trials as Topic; | 2005 |
Developments in the pharmacotherapeutic management of spontaneous preterm labor.
Topics: Female; Fetus; Glucocorticoids; Health Care Costs; Humans; Magnesium Sulfate; Nifedipine; Obstetric | 2008 |
16 trials available for nifedipine and Preterm Birth
| Article | Year |
|---|---|
Effectiveness of an oral versus sublingual loading dose of nifedipine for tocolysis.
Topics: Administration, Oral; Administration, Sublingual; Adult; Brazil; Female; Gestational Age; Humans; Ni | 2020 |
Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial.
Topics: Child Behavior Disorders; Child, Preschool; Executive Function; Female; Follow-Up Studies; Health St | 2020 |
The effectiveness of nifedipine/indomethacin combination therapy and nifedipine monotherapy for postponing preterm birth (25-34 weeks of gestation) in Sudanese women: a randomized clinical trial study protocol.
Topics: Adolescent; Adult; Combined Modality Therapy; Female; Gestational Age; Humans; Indomethacin; Infant, | 2021 |
Effect of nifedipine and atosiban on perinatal brain injury: secondary analysis of the APOSTEL-III trial.
Topics: Administration, Intravenous; Adult; Brain Injuries; Female; Gestational Age; Humans; Infant, Newborn | 2018 |
Nifedipine alone or combined with sildenafil citrate for management of threatened preterm labour: a randomised trial.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Drug Monitoring; Drug Synergism; Female; | 2019 |
Cost effectiveness of nifedipine compared with atosiban in the treatment of threatened preterm birth (APOSTEL III trial).
Topics: Cost-Benefit Analysis; Female; Humans; Nifedipine; Pregnancy; Pregnancy, Multiple; Premature Birth; | 2019 |
A comparative study on the efficacy of nifedipine and indomethacin for prevention of preterm birth as monotherapy and combination therapy: a randomized clinical trial.
Topics: Female; Humans; Indomethacin; Infant; Infant, Newborn; Nifedipine; Obstetric Labor, Premature; Pregn | 2020 |
The NIFTY study: a multicentre randomised double-blind placebo-controlled trial of nifedipine maintenance tocolysis in fetal fibronectin-positive women in threatened preterm labour.
Topics: Adult; Double-Blind Method; Female; Fibronectins; Gestational Age; Humans; Infant, Newborn; Kaplan-M | 2014 |
Prophylactic oral nifedipine to reduce preterm delivery: a randomized controlled trial in women at high risk.
Topics: Administration, Oral; Adult; Asymptomatic Diseases; Cervical Length Measurement; Double-Blind Method | 2014 |
Comparison between nitroglycerin dermal patch and nifedipine for treatment of preterm labor: a randomized clinical trial.
Topics: Apgar Score; Birth Weight; Cesarean Section; Female; Gestational Age; Humans; Infant, Newborn; Inten | 2014 |
Single versus combination tocolytic regimen in the prevention of preterm births in women: a prospective cohort study.
Topics: Albuterol; Drug Therapy, Combination; Female; Humans; Nifedipine; Pregnancy; Premature Birth; Prospe | 2015 |
Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial.
Topics: Administration, Intravenous; Administration, Ophthalmic; Adult; Belgium; Calcium Channel Blockers; F | 2016 |
Nifedipine versus placebo in the treatment of preterm prelabor rupture of membranes: a randomized controlled trial: Assessment of perinatal outcome by use of tocolysis in early labor-APOSTEL IV trial.
Topics: Adult; Female; Fetal Membranes, Premature Rupture; Humans; Nifedipine; Obstetric Labor, Premature; P | 2016 |
Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial.
Topics: Adult; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Nifedipine; Obstetric La | 2008 |
Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial.
Topics: Adult; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Nifedipine; Obstetric La | 2008 |
Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial.
Topics: Adult; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Nifedipine; Obstetric La | 2008 |
Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial.
Topics: Adult; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Nifedipine; Obstetric La | 2008 |
The effects of the tocolytics atosiban and nifedipine on fetal movements, heart rate and blood flow.
Topics: Adult; Algorithms; Betamethasone; Drug Combinations; Female; Fetal Blood; Fetal Movement; Heart Rate | 2009 |
Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor.
Topics: Adult; Drug Administration Schedule; Female; Humans; Indomethacin; Nifedipine; Obstetric Labor, Prem | 2011 |
20 other studies available for nifedipine and Preterm Birth
| Article | Year |
|---|---|
Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study.
Topics: Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension, Pregnancy-Induced; Infant; Infa | 2022 |
Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium.
Topics: Aminophylline; Female; Humans; Indomethacin; Infant, Newborn; Myometrium; Nifedipine; Pregnancy; Pre | 2023 |
Trends in antihypertensive prescription for pregnant women with hypertension and their peripartum outcomes before and after label and guideline revisions in Japan.
Topics: Antihypertensive Agents; Cesarean Section; Drug Prescriptions; Female; Humans; Hydralazine; Hyperten | 2022 |
Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth.
Topics: Animals; Female; Humans; Infant, Newborn; Mice; Myometrium; Nifedipine; Obstetric Labor, Premature; | 2023 |
Arrest of mouse preterm labor until term delivery by combination therapy with atosiban and mundulone, a natural product with tocolytic efficacy.
Topics: Animals; Biological Products; Female; Humans; Infant, Newborn; Mice; Mifepristone; Nifedipine; Obste | 2023 |
Bryophyllum pinnatum enhances the inhibitory effect of atosiban and nifedipine on human myometrial contractility: an in vitro study.
Topics: Adult; Drug Antagonism; Female; Humans; In Vitro Techniques; Kalanchoe; Myometrium; Nifedipine; Plan | 2019 |
Effects of nifedipine on endothelial function, assessed by flow-mediated vasodilatation in pregnant patients.
Topics: Adult; Female; Humans; Infant; Infant, Newborn; Nifedipine; Obstetric Labor, Premature; Pregnancy; P | 2022 |
The importance of cost considerations in preterm birth trials.
Topics: Cost-Benefit Analysis; Female; Humans; Infant, Newborn; Nifedipine; Pregnancy; Premature Birth; Vaso | 2019 |
Preterm labor: current tocolytic options for the treatment of preterm labor.
Topics: Adrenergic beta-Agonists; Female; Glucocorticoids; Humans; Infant, Newborn; Nifedipine; Obstetric La | 2014 |
Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births.
Topics: Adult; Azithromycin; Case-Control Studies; Drug Synergism; Erythromycin; Female; Humans; Infant, New | 2014 |
What is the risk of preterm delivery after arrested preterm labor?
Topics: Adult; Case-Control Studies; Cervical Length Measurement; Cervix Uteri; Cohort Studies; Female; Fibr | 2015 |
Tocolysis and preterm labour.
Topics: Calcium Channel Blockers; Female; Humans; Nifedipine; Pregnancy; Premature Birth; Tocolytic Agents; | 2016 |
A new paradigm for the role of smooth muscle cells in the human cervix.
Topics: Adult; Cervix Uteri; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Middle | 2016 |
Nifedipine increases fetoplacental perfusion.
Topics: Adult; Female; Hemodynamics; Humans; Nifedipine; Placental Circulation; Pregnancy; Premature Birth; | 2017 |
Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor.
Topics: Albuterol; Animals; Drug Delivery Systems; Female; Indomethacin; Liposomes; Mice; Myometrium; Nifedi | 2017 |
[Treatment of preterm delivery with calcium channel blockers--Nifedipine].
Topics: Calcium Channel Blockers; Female; Gestational Age; Humans; Nifedipine; Obstetric Labor, Premature; P | 2007 |
[Nifedipine or nicardipine in management of threatened preterm delivery: an observational population-based study].
Topics: Adult; Calcium Channel Blockers; Female; France; Humans; Nicardipine; Nifedipine; Pregnancy; Prematu | 2010 |
Potentiation of the uterus-relaxing effects of β-adrenergic agonists with nifedipine: studies on rats and the human myometrium.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Drug Synergism; Drug Therapy, Combination; Female; Hum | 2010 |
Pregnancy outcomes in a recurrent preterm birth prevention clinic.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Cervical Length Measurement; Clinical Protocols; Cohort Studies | 2011 |
Expression of selected genes in preterm premature rupture of fetal membranes.
Topics: Adult; Calcium Channel Blockers; Calcium Channels, L-Type; Celecoxib; Cyclooxygenase 2 Inhibitors; D | 2012 |